In preparation for the Consumer Healthcare Products Association’s 2015 Annual Executive Conference being held in Bonita Springs, Fla., this month, Drug Store News sat down with both Scott Melville, CHPA president and CEO, and Patrick Lockwood-Taylor, CHPA chair and VP personal health care, North America, for Procter & Gamble.
Drug Store News has partnered with Competitive Promotion Report and IRI to create a series of exclusive reports. This edition explores cold/allergy/sinus products in both the liquid/powder and tablets/packets segments.
Miraculins in January announced that it will be commencing a pilot program with Lovell Drugs and Pear Healthcare Solutions that will see the placement of the first stand-alone Scout DS diabetes screening kiosks in Lovell’s retail pharmacy locations in Ontario beginning in February.
DexCom received Food and Drug Administration approval for its Dexcom G4 Platinum Continuous Glucose Monitor System with Share. The Share receiver uses a wireless connection via Bluetooth Low Energy between the patient’s receiver and an app on the patient’s smartphone to relay glucose information to apps on the mobile devices of up to five designated recipients, or “followers.”
In a meeting with nearly two dozen leaders representing consumers, insurers, providers and business leaders, Health and Human Services Secretary Sylvia Burwell on Jan. 26 announced measurable goals and a timeline to move the Medicare program, and the healthcare system at large, toward paying providers based on the quality of care they give patients.
Tooth decay is one of the most common chronic conditions among children in the United States, according to the Centers for Disease Control and Prevention, with about 20% of children ages 5 years to 11 years old having at least one untreated decayed tooth. The good news is that tooth decay is preventable.
The introduction in January of bipartisan legislation that would grant retail pharmacists provider status for Medicare patients in “underserved” communities certainly sounds like a step in the right direction.
While the big four analgesic manufacturers — Bayer, Pfizer, McNeil and Novartis — command the lion’s share of retail ad support behind their mega analgesic brands, Prestige Brands and BedRock Brands are making headway promoting their niche pain relieving products.